04:34 AM EDT, 07/14/2025 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said Sunday that an analysis of a phase 2b clinical trial of a 90-milligram dose of its investigational drug avexitide for the treatment of post-bariatric hypoglycemia led to a 64% least-squares mean reduction versus baseline in certain types of hypoglycemic events.

More than half of the participants experienced no events, the results showed. The company also reported "consistent reductions" in hypoglycemic events with 45 mg and 30 mg twice daily and 60 mg doses in a phase 2 trial.

A phase 3 clinical trial with 75 patients is also underway.

Post-bariatric hypoglycemia is a condition that impacts patients who have undergone certain types of bariatric surgery, leading to hypoglycemia and poorer quality of life.

Amylyx shares were up 2.2% in recent premarket activity Monday.